This collaboration marks the most recent implementation of ArcticZymes new channel strategy and will significantly enhance the accessibility of ArcticZymes' innovative salt-active nuclease in Europe. These products are used in a broad range of bioprocessing applications including the rapidly growing areas of gene therapy, vaccine manufacturing, and other advanced therapeutic modalities.

The SAN-HQ and M-SAN enzymes from ArcticZymes offer technically superior performance under both physiological and high-salt conditions, providing reliable and efficient removal of nucleic acids in complex manufacturing environments. ArcticZymes is the only company to offer specific nuclease solutions, designed and optimised to work at physiological or high salt concentrations.

• M-SAN is optimised for use with processes which favour physiological salt concentrations.

• SAN-HQ is designed for application which required a salt concentration, to reduce aggregates.

Both enzymes are available in research and GMP-grade formats, ensuring a smooth transition from development to full-scale commercial manufacturing.

Paul Blackburn, Chief Commercial Officer of ArcticZymes Technologies, commented: 
"This partnership with Brenntag represents an important step in expanding our presence across Europe and making our innovative salt-active nucleases more accessible to biopharmaceutical customers. Brenntag's strong regional footprint, technical expertise, and proven customer relationships make them an ideal partner for our existing commercial team to accelerate growth and support our mission to enable advanced biomanufacturing."

Joakim Rehné, Regional President, Brenntag Pharma EMEA, added: 
"Our partnership with ArcticZymes for SAN HQ and M-SAN HQ marks a milestone in Brenntag's commitment to the biopharmaceutical industry. By expanding our portfolio with high-quality enzymes, we support our customers from the early research phase through to full commercialization."

Through this collaboration, both companies reaffirm their commitment to supporting the rapidly growing therapeutic bioprocessing market by delivering high-quality, compliant, and scalable enzyme solutions that meet the evolving needs of therapeutic manufacturing.

About ArcticZymes Technologies ASA

Headquartered in Tromsø, Norway, ArcticZymes Technologies ASA is a publicly listed, leading provider of novel and high-quality enzymes for use in molecular research, diagnostics, and biomanufacturing. With over 30 years of expertise, the company develops and manufactures salt-active nucleases and other specialty enzymes inspired by the Arctic environment, enabling robust performance under demanding process conditions. ArcticZymes is certified to ISO 13485 and manufactures under relevant ICH GMP standards. 
For more information, visit www.arcticzymes.com.

About Brenntag

Brenntag is the global market leader in chemicals and ingredients distribution. Headquartered in Essen, Germany, the company operates a network of around 600 sites in more than 70 countries and employs over 18,000 people. In 2024, Brenntag generated sales of EUR 16.2 billion. Through its two global divisions, Brenntag Essentials and Brenntag Specialties, the company provides a comprehensive range of industrial and specialty chemicals, technical support, and supply chain solutions. Brenntag is listed on the Frankfurt Stock Exchange and included in the DAX, DAX 30 ESG, and DAX ESG Target indices. 
For more information, visit www.brenntag.com.

Press Contacts

ArcticZymes Technologies ASA 
Steve Dey, Global Director of Product Management and Marketing 
E-mail: steve.dey@arcticzymes.com 
Website: www.arcticzymes.com

Brenntag SE 
Helmut Weintögl, Director Communications EMEA 
E-mail: helmut.weintoegl@brenntag.com 
Phone: +49 (201) 6496-1339 
Website: www.brenntag.com